Page 26 - Cipla

Cipla to enter Brazil, China with emerging market focus

Furthering a strategy of expanding in India, South Africa and US markets

Cipla's Q3 net profit jumps by 44% to Rs 375 cr

Net sales during the quarter under review stood at Rs 3,550.02 crore

Cipla gets UK nod to sell key inhaler for asthmatics

Firm's Sereflo inhaler is a generic version of GSK's Advair, has a market size of $278 mn in Britain

Cipla up 5% on UK MHRA approval for generic asthma drug

The stock gained 5% to Rs 589, bouncing back 6.5% from intra-day low on the BSE

Cipla sells 16.7% stake in Chase Pharma to Allergan

Cipla UK had acquired a minority stake in Chase in May 2014 via a syndicated venture investment

Cipla plans to get more aggressive in US, UK

The market size for blockbuster inhaler Seretide in Britain was $400 million last year, say analysts

Cipla Q2 profit falls as Europe, emerging markets suffer

Sales in India, Cipla's biggest market, rose 21% in the quarter

Cipla is back to old strategy with a twist

US likely to bring significant growth

Blow to Cipla; company loses court battle in drug-overcharging case

Company had received notices of demand aggregating to Rs 1,768 cr

Cipla signs deal to set up first biosimilars unit in South Africa

The agreement with KwaZulu-Natal Dube Trade Port SEZ for Cipla BIOTEC's new facility was concluded during the BRICS Summit

Cipla gains as Indore plant gets US FDA clearance

The stock was up 3% to Rs 596 on the BSE in early morning trade.

Cipla's Indore plant cleared by FDA

The clearance indicates the formal closure of the US FDA inspection conducted in July/August, 2015

Concerns aggravate for Cipla, Alkem

More worries for Alkem, as its Daman plant, which is under scanner, is crucial for US growth

Cipla falls on heavy volumes

The stock dipped 6% to Rs 562 in intra-day trade on media reports that the USFDA inspected the company's Goa facility.

Drug firms facing challenging times due to price control: Cipla

Tightening of new product registration procedures also impacting industry

Cipla gets USFDA nod for generic anti-depressant drug

Company's shares were today trading at Rs 570.25 per scrip in the afternoon trade on BSE, up 0.54% from its previous close

Cipla, Godrej recognised in Fortune Change the World list

Fortune lauded Cipla for driving prices down for much-needed medications

Street positive on Cipla despite weak results

Base business growth in the US, and bottoming out of operating-profit margins are key positives

Cipla gains post June quarter results

The stock was up 5% at Rs 540 on the NSE, as compared to 0.57% fall in the Nifty 50 index at 12:49 pm.

Cipla's net profit dips 44%, announces new CEO

Overall revenue of Cipla falls 6%; international business drops 14%